Noa Therapeutics Inc.

Profile

Noa Therapeutics is pioneering the development of novel small-molecule therapeutics for the tailored treatment of inflammatory diseases involving barrier dysfunction. The company’s suite of singular, non-steroidal, small molecules simultaneously resolves dysregulated immune and barrier transcriptional pathways to address complex unmet needs in >$100B inflammatory barrier disease markets. Starting with a first use case in atopic dermatitis, Noa is actively expanding the pipeline of unique NCEs for secondary indications including ulcerative colitis, and multiple sclerosis.

Website

noatherapeutics.com

Contact


Event details

Date: November 4 - 6, 2024

Event contact

Rita Patlan
Area Director
Europe: Aerospace and Defence, Environmental Technologies and Infrastructure

Participants

12 in total